Pulmotect
Latest round
- Series C
Last raised
- Aug 2024
Total raised
- $16M
Investors
- 4
About Pulmotect
Pulmotect, Inc.Founded in 2007 and headquartered in Houston, US, Pulmotect, Inc. specializes in creating unique inhaled therapies.Pulmotect, Inc. specializes in the development of innovative inhaled therapeutics, with a primary focus on its lead product, PUL-042. This first-in-class, patent-protected therapy activates the innate immune system within the lungs, offering immediate protection against various pathogens. PUL-042 is currently in clinical development, having undergone Phase I/2a trials to establish its safety and tolerability among healthy individuals and patients with chronic obstructive pulmonary disease (COPD).Pulmotect's revenue strategy relies on the commercialization of its proprietary product, PUL-042, as it advances through clinical trials and regulatory approval. Revenue is expected from partnerships with healthcare providers and institutions, or direct sales to entities managing respiratory disease patient care.In August 2024, Pulmotect, Inc. The company plans to extend its product offerings and target expansion into new markets across North America and Europe.
Who invested in Pulmotect
4 investors across 3 rounds
See all investors in Pulmotect
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Pulmotect
Who invested in Pulmotect?
Pulmotect has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pulmotect raised?
Pulmotect has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Pulmotect last raise money?
Pulmotect's most recent round on record is a Series C, in Aug 2024.
What does Pulmotect do?
Pulmotect is a pharmaceuticals company.
Where is Pulmotect headquartered?
Pulmotect is headquartered in Houston, US.
Which VCs invest in companies like Pulmotect?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Pulmotect's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Pulmotect? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.